Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
BLUE

BLUE - Bluebird Bio Inc Stock Price, Fair Value and News

0.97USD-0.03 (-3.00%)Market Closed

Market Summary

BLUE
USD0.97-0.03
Market Closed
-3.00%

BLUE Stock Price

View Fullscreen

BLUE RSI Chart

BLUE Valuation

Market Cap

112.6M

Price/Earnings (Trailing)

-1.19

Price/Sales (Trailing)

4.98

EV/EBITDA

0.66

Price/Free Cashflow

-0.39

BLUE Price/Sales (Trailing)

BLUE Profitability

Operating Margin

-9.98%

EBT Margin

-419.48%

Return on Equity

-40.97%

Return on Assets

-14.86%

Free Cashflow Yield

-259.24%

BLUE Fundamentals

BLUE Revenue

Revenue (TTM)

21.7M

Rev. Growth (Yr)

17.6K%

Rev. Growth (Qtr)

79.85%

BLUE Earnings

Earnings (TTM)

-91.2M

Earnings Growth (Yr)

6.26%

Earnings Growth (Qtr)

1.61%

Breaking Down BLUE Revenue

Last 7 days

6.6%

Last 30 days

-9.3%

Last 90 days

-31.7%

Trailing 12 Months

-75.7%

How does BLUE drawdown profile look like?

BLUE Financial Health

Current Ratio

1.55

BLUE Investor Care

Shares Dilution (1Y)

31.87%

Diluted EPS (TTM)

-1.41

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20234.0M9.4M21.7M0
20224.7M6.1M5.1M3.6M
2021189.0M127.2M65.4M3.7M
202054.1M239.7M250.0M250.7M
201951.1M56.5M53.9M44.7M
201844.6M35.7M39.5M54.6M
201711.5M26.7M32.8M35.4M
20169.2M5.8M6.1M6.2M
201525.4M24.0M19.0M14.1M
201425.4M25.4M25.4M25.4M
20131.4M7.6M13.9M20.2M
20120274.7K307.3K340.0K
2011000242.0K

Tracking the Latest Insider Buys and Sells of Bluebird Bio Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 03, 2024
klima thomas j
sold
-3,726
0.9719
-3,834
see remarks
Mar 04, 2024
klima thomas j
sold
-6,985
1.5276
-4,573
see remarks
Mar 04, 2024
obenshain andrew
sold
-9,310
1.5276
-6,095
president and ceo
Mar 01, 2024
colvin richard a
sold
-10,341
1.5276
-6,770
chief medical officer
Feb 05, 2024
klima thomas j
sold
-2,449
0.9025
-2,714
see remarks
Feb 05, 2024
obenshain andrew
sold
-1,695
0.9025
-1,879
president and ceo
Feb 05, 2024
vittiglio joseph
sold
-4,708
0.9025
-5,217
chief business & legal officer
Jan 05, 2024
obenshain andrew
sold
-4,519
1.4294
-3,162
president and ceo
Jan 05, 2024
colvin richard a
sold
-844
1.415
-597
chief medical officer
Dec 06, 2023
krawtschuk christopher
sold
-20,437
4.5155
-4,526
chief financial officer

1–10 of 50

Which funds bought or sold BLUE recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 11, 2024
EverSource Wealth Advisors, LLC
sold off
-100
-242
-
-%
May 24, 2024
FARALLON CAPITAL MANAGEMENT LLC
sold off
-100
-2,760,000
-
-%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
189
29,822
46,822
0.01%
May 20, 2024
Highlander Capital Management, LLC
sold off
-100
-690
-
-%
May 20, 2024
Virtu Financial LLC
sold off
-100
-317,000
-
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
added
9.32
339
24,648
-%
May 16, 2024
COMERICA BANK
sold off
-100
-835
-
-%
May 16, 2024
Colony Group, LLC
added
277
106,000
148,000
-%
May 16, 2024
JANE STREET GROUP, LLC
added
135
559,011
1,030,100
-%
May 15, 2024
Lion Point Capital, LP
added
59.67
352,635
1,085,770
0.61%

1–10 of 44

Are Funds Buying or Selling BLUE?

Are funds buying BLUE calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own BLUE
No. of Funds

Unveiling Bluebird Bio Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 10, 2024
state street corp
1.80%
3,428,135
SC 13G/A
Feb 14, 2024
alyeska investment group, l.p.
6.32%
6,912,502
SC 13G
Feb 14, 2024
pfm health sciences, lp
1.9%
6
SC 13G/A
Feb 14, 2024
tang capital partners lp
0.9%
1,700,000
SC 13G/A
Feb 14, 2024
granahan investment management, llc
7.38%
8,077,697
SC 13G
Feb 13, 2024
vanguard group inc
4.61%
8,775,379
SC 13G/A
Feb 06, 2024
goldman sachs group inc
6.4%
12,181,040
SC 13G
Jan 25, 2024
state street corp
7.28%
13,865,719
SC 13G/A
Jan 08, 2024
blackrock inc.
4.7%
8,983,001
SC 13G/A
Apr 21, 2023
pfm health sciences, lp
5.7%
6
SC 13G

Recent SEC filings of Bluebird Bio Inc

View All Filings
Date Filed Form Type Document
Jun 13, 2024
3
Insider Trading
Jun 04, 2024
4
Insider Trading
May 29, 2024
8-K
Current Report
May 15, 2024
NT 10-Q
NT 10-Q
May 09, 2024
8-K
Current Report
May 03, 2024
8-K
Current Report
Apr 26, 2024
8-K
Current Report
Apr 16, 2024
8-K
Current Report
Apr 10, 2024
SC 13G/A
Major Ownership Report
Mar 26, 2024
NT 10-K
NT 10-K

Peers (Alternatives to Bluebird Bio Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
53.7B
6.8B
8.51% 7.74%
-8.99
7.84
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.3B
2.0B
8.81% -20.73%
-61.09
10.13
75.20% 68.82%
15.9B
2.5B
3.83% -12.90%
77.15
6.41
13.74% 186.89%
13.9B
3.8B
8.85% -0.77%
18.71
3.7
8.58% 129.81%
MID-CAP
5.2B
107.9M
-7.07% 79.45%
-9.53
48.09
54.84% -28.31%
5.1B
524.1M
0.17% -53.14%
-12.21
9.72
394.93% 39.61%
3.5B
251.0M
-2.92% -12.90%
-11.81
13.95
73.58% -86.73%
3.2B
240.7M
3.27% -27.64%
-6.79
12.77
-1.03% -213.92%
2.5B
813.8M
-1.46% -38.91%
-1.4K
3.03
56.43% 98.83%
2.0B
996.6M
11.55% 78.54%
-5.07
2.03
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-9.60% 21.75%
27.32
4.32
60.38% -34.49%
534.3M
881.7K
13.28% 545.16%
-15.83
481.06
-77.61% 33.36%
235.5M
4.2M
-30.45% 48.53%
-1.89
56.62
-66.30% 48.24%
22.1M
2.1M
36.17% 264.31%
-0.95
7.61
-13.45% 69.54%

Bluebird Bio Inc News

Latest updates
Yahoo New Zealand News11 Jun 202412:28 pm
The Motley Fool16 May 202407:00 am
Seeking Alpha09 May 202407:00 am
The Motley Fool2 months ago

Bluebird Bio Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue79.9%12,392,0006,890,0002,381,00063,00070,0001,519,0001,945,0001,606,0001,019,000143,0005,425,50010,708,00019,273,000198,890,00021,863,0009,997,0008,910,00013,296,00012,471,00019,243,00011,528,000
Cost Of Revenue14.5%10,955,0009,564,0003,376,000--1,745,0008,310,000--------------
Gross Profit153.7%1,437,000-2,674,000-995,000-71,000-226,000-6,365,000--------------
Costs and Expenses4.3%86,166,00082,623,00083,498,00086,683,00084,852,000107,174,000113,981,000137,273,000155,468,000154,844,000146,988,000139,387,000131,743,000143,650,000144,479,000240,531,000219,326,000215,998,000183,645,000176,204,000161,347,000
Operating Expenses--------------------176,204,000161,347,000
  S&GA Expenses0.9%40,703,00040,349,00037,354,00030,706,50033,402,00036,694,00036,106,00051,196,50042,229,00054,984,00063,569,00030,028,00068,046,00068,628,00073,248,00040,684,00066,250,00068,631,00060,279,00053,508,00044,527,000
  R&D Expenses7.5%45,463,00042,274,00046,144,00045,899,50053,149,00063,841,00077,875,00079,082,00073,679,00084,645,00082,843,000-131,553,000140,431,000156,308,000154,123,000-93,473,000151,412,000146,540,000122,640,000119,722,000116,744,000
EBITDA Margin58.8%-3.99-9.70-29.26-72.69-82.68-81.59-116-148-8.40-4.66-2.43-2.16---------
Income Taxes100.0%--80,000-110,0007,000--89,000-113,000216,00066,000253,000329,00010,00094,000203,000-264,000-469,000-15,000--
Earnings Before Taxes1.7%-71,731,000-72,988,00021,240,00032,342,000-76,513,000-100,138,000-122,152,000-132,238,000-152,947,000-155,757,000-121,438,000-141,982,000-194,416,000-21,455,000-202,517,00011,442,000-206,297,000-196,251,000-164,461,000-148,836,000-145,480,000
EBT Margin58.9%-4.19-10.20-30.52-74.08-83.86-83.34-119-153-8.74-4.82-2.54-2.23---------
Net Income1.6%-71,731,000-72,908,00021,240,00032,232,000-76,520,000-100,138,000-122,152,000-155,052,000-216,816,000-241,702,000-205,808,000-199,874,000-194,745,000-21,465,000-202,611,000-223,347,000-206,033,000-195,782,000-164,446,000-149,023,000-145,480,000
Net Income Margin58.9%-4.20-10.20-30.54-74.11-88.30-97.58-156-223-13.21-6.62-3.29-2.47---------
Free Cashflow13.0%-63,884,000-73,467,000-86,870,000-56,381,000-78,290,000-100,337,000-126,153,000-141,284,000-150,679,000-147,226,000-210,953,000-163,081,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-7.5%6146636935555205744915941,3401,4541,6371,7811,9452,1081,5291,7271,8922,0232,1392,2432,352
  Current Assets-14.2%2472883511991601672553378329041,0981,2161,2931,6139671,1521,2201,3011,3651,4191,725
    Cash Equivalents-4.4%16517323911366.0081.001062074023534403743241,199347382300281222417952
  Inventory53.7%21.0014.004.00-----1.0014.0018.0011.00---------
  Net PPE-2.5%10.0010.009.009.0012.0015.0011.0010.0046.0015916517.00158155154151144129114247233
  Goodwill0%6.006.006.006.006.006.006.006.0012.0013.0013.006.0013.0013.0013.0013.0013.0013.0013.0013.0013.00
Liabilities4.5%391374338359361393228220469470437426422426409442421387367358351
  Current Liabilities17.7%159135116128127149143153267248206204197197184224196162147146132
Shareholder's Equity-23.0%2232893551961591802633748719851,2001,3551,5231,6821,1201,2851,4721,6361,7721,8852,001
  Retained Earnings-1.8%-4,109-4,038-3,970-3,986-4,020-3,940-3,842-3,719-3,560-3,350-3,106-2,900-2,700-2,505-2,480-2,281-2,058-1,852-1,656-1,498-1,349
  Additional Paid-In Capital0.1%4,3344,3284,3224,1864,1814,1264,1094,0964,4414,3384,3114,2604,2274,1903,6073,5683,5333,4893,4303,3873,355
Shares Outstanding0.5%10710610683.0082.0074.0074.0071.0068.0067.0067.0062.00---------
Float------302---1,399---4,041---7,025---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations15.0%-61,846-72,763-86,600-56,320-77,026-94,358-125,296-139,725-146,939-145,648-203,327-155,193-148,78039,743-206,121-158,976-113,381-137,873-154,154-129,731-74,473
  Share Based Compensation-15.4%4,8685,7545,3914,6799,2118,90812,39026,08628,14231,16042,52732,99138,81848,52936,29334,63138,54655,11132,34129,98729,798
Cashflow From Investing793.9%62,0836,94582,136103,24215,60961,67669,92660,932119,90560,368321,352148,816-727,015269,276224,578183,253129,041232,426-36,913-421,09133,868
Cashflow From Financing90.6%-42.00-445130,456-11546,3258,0349.00-174,01475,8683963,7961,4321,198543,1229632,0054,1784,78110,2231,921658,793
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

BLUE Income Statement

2023-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue:    
Total revenues$ 12,392$ 71$ 21,663$ 3,534
Cost of product revenue10,955023,89510,056
Gross margin1,43771(2,232)(6,522)
Operating expenses:    
Selling, general and administrative40,70333,402118,406106,201
Research and development45,46353,149133,881194,864
Restructuring expenses0(1,699)04,940
Total operating expenses86,16684,852252,287306,005
Gain from sale of priority review voucher, net0092,9300
Income (loss) from operations(84,729)(84,781)(161,589)(312,527)
Interest income, net2,4543837,958663
Other income (expense), net10,5447,88530,15213,061
Income (loss) before income taxes(71,731)(76,513)(123,479)(298,803)
Income tax (expense) benefit0(7)80(7)
Net income (loss)$ (71,731)$ (76,520)$ (123,399)$ (298,810)
Net income (loss) per share - basic (in dollars per share)$ (0.66)$ (0.94)$ (1.15)$ (3.91)
Net income (loss) per share - diluted (in dollars per share)$ (0.66)$ (0.94)$ (1.15)$ (3.91)
Weighted-average number of common shares used in computing net income (loss) per share - basic (in shares)109,09881,543106,92476,361
Weighted-average number of common shares used in computing net income (loss) per share - diluted (in shares)109,09881,543106,92476,361
Other comprehensive income (loss):    
Total other comprehensive income (loss)$ 137$ (214)$ 1,843$ (1,719)
Comprehensive income (loss)(71,594)(76,734)(121,556)(300,529)
Product revenue, net    
Revenue:    
Revenue12,281021,4142,739
Other revenue    
Revenue:    
Revenue$ 111$ 71$ 249$ 795

BLUE Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets (unaudited) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 165,347$ 113,006
Marketable securities8,94667,321
Accounts receivable23,0000
Prepaid expenses11,4318,374
Inventory20,9690
Other current assets17,38310,787
Total current assets247,076199,488
Marketable securities01,414
Property, plant and equipment, net9,9729,362
Goodwill5,6465,646
Intangible assets5,3684,868
Operating lease right-of-use assets294,717281,996
Restricted cash and other non-current assets50,82952,128
Total assets613,608554,902
Current liabilities:  
Accounts payable19,85225,092
Deferred revenue9,6531,502
Accrued expenses and other current liabilities57,76850,483
Operating lease liability, current portion71,68451,160
Total current liabilities158,957128,237
Operating lease liability, net of current portion232,023230,230
Other non-current liabilities9292
Total liabilities391,072358,559
Commitments and contingencies (Note 9)
Stockholders’ equity:  
Preferred stock, $0.01 par value, 5,000 shares authorized; 0 shares issued and outstanding at September 30, 2023 and December 31, 202200
Common stock, $0.01 par value, 250,000 shares authorized; 107,022 and 82,923 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively1,071830
Additional paid-in capital4,333,5944,186,086
Accumulated other comprehensive loss(2,227)(4,070)
Accumulated deficit(4,109,902)(3,986,503)
Total stockholders’ equity222,536196,343
Total liabilities and stockholders’ equity$ 613,608$ 554,902
BLUE
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.
 CEO
 WEBSITEbluebirdbio.com
 INDUSTRYBiotechnology
 EMPLOYEES323

Bluebird Bio Inc Frequently Asked Questions


What is the ticker symbol for Bluebird Bio Inc? What does BLUE stand for in stocks?

BLUE is the stock ticker symbol of Bluebird Bio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bluebird Bio Inc (BLUE)?

As of Fri Jun 14 2024, market cap of Bluebird Bio Inc is 112.62 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BLUE stock?

You can check BLUE's fair value in chart for subscribers.

What is the fair value of BLUE stock?

You can check BLUE's fair value in chart for subscribers. The fair value of Bluebird Bio Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Bluebird Bio Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BLUE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Bluebird Bio Inc a good stock to buy?

The fair value guage provides a quick view whether BLUE is over valued or under valued. Whether Bluebird Bio Inc is cheap or expensive depends on the assumptions which impact Bluebird Bio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BLUE.

What is Bluebird Bio Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 14 2024, BLUE's PE ratio (Price to Earnings) is -1.19 and Price to Sales (PS) ratio is 4.98. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BLUE PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Bluebird Bio Inc's stock?

In the past 10 years, Bluebird Bio Inc has provided -0.304 (multiply by 100 for percentage) rate of return.